Management

Tore Duvold CEO

Born in 1968.
Member of the board and Chief Executive Officer since September 2020.

Education and experience:
Tore Duvold has more than 20 years' experience in the pharmaceutical and biotechnology industries, with extensive experience in dermatological diseases, antibiotics and kidney diseases. Tore Duvold was the CEO of Aker Biopharma AS and Senior Vice President and part of the Group management of LEO Pharma. His most recent position was at Innovation Fund Denmark, where he took up position as Vice President and was later appointed Chief Executive Officer. Tore Duvold has held directorships and served in advisory boards at both Technical University of Denmark and University of Copenhagen. Tore Duvold holds a degree in organic chemistry from the University of Bergen and a ph.d dsegree from Université Louis Pasteur in France.

Shareholding:
Tore Duvold owns 1,000,000 warrants i Coegin Pharma AB.

Berit Johansen CSO

Born in 1958.

Education and experience:
Berit Johansen has been active in Coegin Pharma from the start in 2005. She is a Professor of Molecular Genetics at the Norwegian University of Science and Technology (NTNU) and the principal inventor of the Company's anti-inflammatory treatment method. Berit Johansen's international academic career includes positions at the Molecular Biology Institute of UCLA, the Biomedical Center of the University of Uppsala, Sweden, NTH,  Department of Biotechnology, and the Institute of Molecular Genetics at University of Göttingen, Germany. Berit Johansen has also held positions as visiting researcher at Biogen Research Corporation, Cambridge, MA, the Department of Chemistry and Biochemistry, University of California, San Diego, CA, and Brigham & Women's Hospital at Harvard University, Boston, USA.

Shareholding:
Berit Johansen owns 3,873,611 shares in Coegin Pharma AB, through the wholly-owned company Beio Holding AS, and, privately, 1,000,000 warrants.